A father picks up his young child and give them a kiss.

Financial Story

Investors

Path to grow: Reset. Strengthen. Strive.

Investors > Overview
Join us for an event

Events & Presentations

Endo Financial Results - Third Quarter 2024
Tuesday, November 5, 2024
8:30am - 9:30am EST
Latest News
Nov 20, 2024
John Elway Teams Up with Endo to Share Update on Dupuytren's Contracture and Treatment with XIAFLEX® (collagenase clostridium histolyticum)

Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment with XIAFLEX® (collagenase...

Nov 18, 2024
Endo Expands Voluntary Recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) Due to Potential Product Carton Strength Mislabeling

Endo, Inc. (OTCQX: NDOI) ("Endo") announced today that one of its operating subsidiaries, Endo USA, Inc., is expanding its previously announced voluntary recall of Clonazepam Orally Disintegrating...

Nov 15, 2024
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in Canada

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream (calcipotriene and betamethasone...

View All Press Releases

Our Board

Governance

Endo’s board of directors oversees and advises our leaders to protect the long-term interests of the company and our shareholders. The experienced and independent board members are committed to building sustainable success.

Directors Committees Policies & Guidelines

Overview

This is body copy - it will be turned off in site mgr